The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global sales last year. A number of Pfizer products, including blood thinner Fragmin and leukemia drug Nipent are also among the first drugs slated for rebates.
CMS’ Medicare Prescription Drug Inflation Rebate Program (MPDIRP) targets prescription drug products whose prices have risen faster than the rate of inflation.
The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
